SimpsonSJrBizzardLOtahalP. Latitude is significantly associated with the prevalence of multiple sclerosis: A meta-analysis. J Neurol Neurosurg Psychiatry2011; 82: 1132–1141.
2.
KurtzkeJFBeebeGWNormanJE. Epidemiology of multiple sclerosis in US veterans: III migration and the risk of MS. Neurology1985; 35: 672–678.
3.
MungerKLZhangSMO’ReillyE. Vitamin D intake and incidence of multiple sclerosis. Neurology2004; 62: 60–65.
4.
MungerKLLevinLIHollisBW. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA2006; 296: 2832–2838.
5.
MowryEMKruppLBMilazzoM. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol2010; 67: 618–624.
6.
CorrealeJYsrraelitMCGaitanMI. Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain2009; 132: 1146–1160.
7.
AdoriniLPennaG. Control of autoimmune diseases by vitamin D endocrine system. Nature Clin Pract Rheumatol2008; 4: 404–412.
8.
AscherioAMungerKLLünemannJD. The initiation and prevention of multiple sclerosis. Nat Rev Neurol2012; 8: 602–612.
9.
KimballSMUrsellMRO’ConnorP. Safety of Vitamin D3 in adults with multiple sclerosis. Am J Clin Nutr2007; 86: 645–651.
10.
BurtonJMKimballSMViethR. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology2010; 74: 1852–1859.
11.
SmoldersJPeelenEThewissenM. Safety and T cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis. PLoS One2010; 5: e15235.
12.
ViethR. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr1999; 69: 842–856.
